FGF15/19 has been known that is able to increase metabolic rate and BAT-mediated energy expenditure concurrently with an increase in fatty acid oxidation, leading to reduced hepatic steatosis and enhanced insulin sensitivity [36]. This evidence concerns the gene INS and fatty liver disease.